Gene:
PML
promyelocytic leukemia

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB annotates drug labels containing pharmacogenetic information approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency, Japan (PMDA), and Health Canada (Santé Canada) (HCSC). PharmGKB annotations provide a brief summary of the PGx in the label, an excerpt from the label and a downloadable highlighted label PDF file. A list of genes and phenotypes found within the label is mapped to label section headers and listed at the end of each annotation. PharmGKB also attempts to interpret the level of action implied in each label with the "PGx Level" tag.

See the legend for more information about drug label sources and PGx Levels.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA, PMDA, HCSC or other Medicine Agencies around the world - please contact feedback.



last updated 10/25/2013

FDA Label for arsenic trioxide and PML, RARA

Genetic testing required

Summary

The FDA-approved drug label for arsenic trioxide (Trisenox) contains information regarding indication of the drug in patients whose acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. The label also states that some patients treated with arsenic trioxide have experienced symptoms similar to a syndrome called the retinoic-acid-Acute Promyelocytic Leukemia (RA-APL) or APL differentiation syndrome, which can be fatal, and high-dose steroids (dexamethasone 10 mg intravenously BID) should be immediately initiated at the first signs.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for tretinoin and PML, RARA

Genetic testing required

Summary

Tretinoin is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.

There's more of this label. Read more.


last updated 10/25/2013

European Medicines Agency (EMA) Label for arsenic trioxide and PML, RARA

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) contains pharmacogenetic information regarding the indication of arsenic trioxide in patients with APL characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RAR-alpha gene.

There's more of this label. Read more.




last updated 06/08/2015

Health Canada Santé Canada (HCSC) Label for arsenic trioxide and PML, RARA

Genetic testing required

Summary

The product monograph for arsenic trioxide (TRISENOX) states that is indicated for patients with acute promyelotic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic-acid-receptor alpha (PML-RARa) gene expression.

There's more of this label. Read more.


last updated 06/08/2015

Health Canada Santé Canada (HCSC) Label for tretinoin and PML, RARA

Genetic testing required

Summary

Tretinoin (VESANOID) is a derivative of vitamin A (retinol) used for the treatment of skin conditions and acute promyelocytic leukemia (APL). APL is characterized by the translocation t(15;17) and PML/RAR alpha (RARA) fusion protein.

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  None
Alternate Symbols:  MYL; RNF71; TRIM19
PharmGKB Accession Id: PA33439

Details

Cytogenetic Location: chr15 : q24.1 - q24.1
GP mRNA Boundary: chr15 : 74287014 - 74340160
GP Gene Boundary: chr15 : 74277014 - 74343160
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.

External Pathways

Links to non-PharmGKB pathways.

  1. regulation of transcriptional activity by pml - (BioCarta via Pathway Interaction Database)
  2. TGF-beta receptor signaling - (Pathway Interaction Database NCI-Nature Curated)
No related genes are available

Curated Information ?

No related diseases are available

Publications related to PML: 3

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008. Ito Keisuke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The cancer biomarker problem. Nature. 2008. Sawyers Charles L. PubMed